Side-by-side · Research reference

PinealonvsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft12/36 cited

BFDA-ApprovedVerified14/45 cited

Pinealon

Pineal-derived · Neuroprotective

5–10 mgPer cycle doseKhavinson 2014

HumanMechanisticKhavinson 2014

HoursHalf-life (est)

SQ or IM · Daily for 10 days · 1-2×/year

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Pinealon

Tirzepatide

Primary target

Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

—

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

—

02Dosage Protocols

Parameter

Pinealon

Tirzepatide

Standard dose

5–10 mg / day for 10 daysKhavinson 2014

—

Frequency

Once daily during cycle

—

Lower / starter dose

2.5 mg / day

—

Evidence basis

Russian clinical trials + in vitroKhavinson 2014

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Duration

10-day cycles, 1–2× per year

Indefinite for chronic indication

Reconstitution

Bacteriostatic water

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

No specific time

Once weekly, any time of day

Half-life

Hours

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

04Side Effects & Safety

Parameter

Pinealon

Tirzepatide

Injection site reaction

Mild irritation

Mild erythema, pruritus

Long-term safety

Limited Western data

—

Pregnancy / OB

Avoid

Contraindicated

GI symptoms

—

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

Pinealon

·Pregnancy / breastfeeding

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

Pinealon

·Active malignancy (theoretical via gene expression modulation)

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

Pinealon

Tirzepatide

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Injection site

SQ — abdomen preferred.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Daily during cycle, any time.

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Needle

29–31G, 4–8 mm insulin syringe.

Pen-supplied. Research vial: 27–31G insulin syringe.

06Stack Synergy

Pinealon

+ Epitalon

Moderate

View Epitalon →

Pinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.

Pinealon: 5–10 mg SQ · daily × 10 days
Epitalon: 5–10 mg SQ · daily × 10 days (overlap or alternate)
Primary benefit: Neuroprotection + telomere preservation

Khavinson 2014 Khavinson 2003

Tirzepatide

— no documented stacks